1. 樹状細胞による免疫調節

2. ヒトおよびマウスにおける腫瘍抗原および腫瘍免疫の解析

3.T細胞による抗原認識と活性化シグナル

4. 疾病とT細胞応答

5. 自己免疫疾患と関連したヒト自己抗原と、HLAおよびT細胞の解析

6. HLAクラスII結合性ペプチドの構造モチーフの解析

1. 樹状細胞による免疫調節

1. Senju, S. et al.
   Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy.
   Gene Therapy advance online publication, 24 March 2011
2. Ikeda, T. et al.
   Dual effects of TRAIL to suppress autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells.
   J. Immunol. 185: 5259-5267, 2010
3. Senju, S. et al.
   Pluripotent stem cells as source of dendritic cells for immune therapy.
   Int. J. Hematol 91:392-400, 2010
4. Senju, S. et al.
   Pluripotent stem cell-derived dendritic cells for immunotherapy.
   Frontiers in bioscience (Elite edition) 2, 1520-1527, 2010
5. Senju, S. et al.
   Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent.
   Stem cells 27:1021-1031, 2009
6. Fukushima, S. et al.
   Multiple antigen-targeted immunotherapy with a-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells.
   J.Immunotherapy 32: 219-231, 2009
7. Matsunaga, Y. et al.
   Activation of antigen-specific cytotoxic T lymphocytes by b2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic ES cell-derived dendritic cells.
   J. Immunol. 181: 6635-6643, 2008
8. Senju, S. et al.
   Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function.
   Stem cells 25: 2720-2729, 2007
9. Hirata, S. et al.
   Involvement of regulatory T cells in the experimental autoimmune encephalomyelitis-preventive effect of dendritic cells expressing myelin oligodendrocyte glycoprotein plus TRAIL.
   J. Immunol. 178: 918-925, 2007.
10. Motomura, Y.et al.
    Embryonic stem cell-derived dendritic cells expressing Glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
    Cancer Research 66: 2414-2422, 2006.
11. Matsuyoshi, H.et al.
    Therapeutic effect of a-galactosylceramide loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
    Cancer Science 96: 889-896, 2005.
12. Fukuma, D. et al.
    Cancer prevention with semi-allogeneic ES cell-derived dendritic cells.
    Biochem. Biophys. Res. Comm. 335: 5-13, 2005
13. Hirata, S. et al.
    Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand1
    J. Immunol. 174: 1888-1897, 2005
14. Matsuyoshi, H. et al.
    Cancer immunotherapy by genetically modified embryonic stem cell-derived dendritic cells.
    In immunology 2004 (The proceeding of the 12th International Congress of Immunology, ed. By Skamene, E.) Medimond S.r.l. (Bologna, Italy), p487-491, 2004
15. Matsuyoshi, H. et al.
    Enhanced priming of antigen-specific CTL in vivo by transfer of ES cell-derived dendritic cells expressing chemokine along with antigenic protein； application to anti-tumor vaccination.
    J. Immunol. 172: 776-786, 2004
16. Senju, S. et.al.
    Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells.
    Blood 101: 3501-3508, 2003
17. Masuda, M. et al.
    Identification and immunocytochemical analysis of DCNP1, a dendritic cell-associated nuclear proteinBiochem.
    Biochem. Biophys. Res. Comm. 290: 1022-1029, 2002
18. Senju S, et al.
    Immunocytochemical analyses and targeted gene disruption of GTPBP1.
    Mol Cell Biol. 2000 Sep;20(17):6195-200
    PMID: 10938096; UI: 20396297
19. Kudo H, et al.
    Identification of mouse and human GTPBP2, new members of GP-1 family of GTPase.
    Biochem Biophys Res Comm. 2000 Jun;272(2):456-65
    PMID: 10833435 ; UI: 20294863
20. Senju S, et al.
    Identification of human and mouse GP-1, a putative member of a novel G-protein family.
    Biochem Biophys Res Commun. 1997 Feb 13;231(2):360-4.
    PMID: 9070279; UI: 97223458.
    
    

2. ヒトおよびマウスにおける腫瘍抗原および腫瘍免疫の解析

1. Tomita, Y et al.
   A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T lymphocytes reactive to tumor cells.
   Cancer Science 102:697-705, 2011
   
2. Imai, K et al.
   Identification of HLA-A2-restricted CTL epitopes of a novel tumor-associated antigen, KIF20A, overexpressed in pancreatic cancer.
   Brit. J. Cancer 104: 300-307, 2011
3. Tomita, Y et al.
   Peptides derived from human insulin-like growth factor (IGF)-II mRNA binding protein 3 can induce human leukocyte antigen-A-2-restricted cytotoxic T lymphocytes reactive to cancer cells.
   Cancer Science, 102: 71-78, 2011.
   
4. Inoue, M. et al.
   Identification of SPARC as a candidate target antigen for immunotherapy of various cancers.
   Int. J. Cancer, 127: 1393-1403,2010.
   
5. Yokomine, K. et al.
   The Forkhead Box M1 Transcription Factor, as a Possible Immunotherapeutic Tumor-Associated Antigen.
   Int. J. Cancer 126: 2153-2163, 2010.
6. Inoue, M. et al.
   An in vivo model of priming of antigen-specific human CTL by Mo-DC in NOD/Shi-scid IL 2rgamma ^null (NOG) mice.
   Immunol. Lett. 126:67-72, 2009.
   
7. Yoshiaki Ikuta*,Yuki Hayashida*. et al.
   Identification of the H2-Kd-restricted CTL epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice.  
   Cancer Science 100: 132-137, 2009.
8. Imai, K. et al.
   Identification of a novel tumor-associated antigen, Cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric and colorectal cancers.
   Clin. Cancer Res. 14: 6487-6495, 2008.
   
9. Harao, M. et al.
   HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
   Int. J. Cancer 123: 2616-2625, 2008.
10. Motomura, Y. et al.
    HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: Preclinical study using mice.
    Int. J. Oncol.32: 985-990, 2008.
11. Yokomine, K. et al.
    Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in ApcMin/+ mice.
    Cancer Science 98:1930-1935, 2007.
12. Komori, H. et al.
    Identification of HLA-A2- or HLA-A 24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Clin. Cancer Res. 12: 2689-2697, 2006.
13. Hosaka, S. et al.
    Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo.
    Cancer Science 97: 623-632, 2006
14. Yokomine, K.et al.
    Immuniztion with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice.
    Biochem. Biophys. Res. Commun. 343: 269-278, 2006
15. Motomura, Y.et al.
    Embryonic stem cell-derived dendritic cells expressing Glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
    Cancer Research 66: 2414-2422, 2006.
16. Ikuta, Y. et al.
    Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels.
    Clinical Cancer Research 11: 8079-8088, 2005.
17. Guo , Y. et al.
    Direct recognition and lysis of leukemia cells by WT1-specific CD4⁺ T lymphocytes in an HLA class II-restricted manner.
    Blood 106: 1415-1418, 2005.
18. Miyazaki, M.*, Nakatsura, T.*(*Equal contribution)
    DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4⁺T cells and CD8⁺ T cells.
    Cancer Science 96: 695-705, 2005
19. Nakatsura, T. et al.
    Mouse homologue of a novel human oncofetal antigen, Glypican-3, evokes T cell-mediated tumor rejection without autoimmune reactions in mice.
    Clinical Cancer Research 10: 8630-8640, 2004
20. Yoshitake, Y . et al.
    Proliferation potential-related protein, an ideal esophageal cancer antigen for immnotherapy, identified using cDNA microarray analysis.
    Clinical Cancer Research 10: 6437-6448, 2004
21. Monji, M. et al.
    Identification of a novel cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses.
    Clinical Cancer Research 10: 6047-6057, 2004
22. Nakatsura, T. et al.
    Identification of Glypican-3 as a Novel Tumor Marker for Melanoma.
    Clinical Cancer Research 10: 6612-6621, 2004
23. Kobayashi, H. et al.
    Identification of Naturally Processed Helper T-Cell Epitopes from Prostate-Specific Membrane Antigen Using Peptide-Based in Vitro Stimulation
    Clinical Cancer Research 9: 5386-5393, 2003
24. Kai, M. et al.
    Heat shock protein 105 is overexpressed in a variety of human tumors.
    Oncology reports 10: 1777-1782, 2003
25. Nakatsura, T. et al.
    Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.
    Biochem. Biophys. Res. Commun. 306: 16-25, 2003
26. Monji, M. et al.
    Head andneck cancer antigens recognized by the humoral immune system
    Biochem. Biophys. Res. Commun. 294: 734-741, 2002
27. Nakatsura, T. et al.
    Cellular and Humoral Immune Responses to A Human Pancreatic Cancer Antigen, CLP, Originally Defined by the SEREX Method
    Eur. J. Immunol. 32: 826-836, 2002
28. Nakatsura, T. et al.
    Gene cloning of immunogenic antigens over-expressed in pancreatic cancer.
    Biochem Biophys Res Comm. 281: 936-944, 2001
29. Maeda A, et al.
    Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, cancer-associated retinopathy antigen, to achieve a clinical better prognosis in a paraneoplastic syndrome.
    Eur J Immunol. 31: 563-572, 2002
30. Yasukawa M, et al.
    Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia.
    Am J Hematol. 2000 Feb;63(2):99-101.
    PMID: 10629577; UI: 20096462
31. Yun C, et al.
    Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein.
    Tissue Antigens. 1999 Aug;54(2):153-61.
32. Yasukawa M, et al.
    CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
    Blood. 1998 Nov 1;92(9):3355-61.
33. Tanaka Y, et al.
    Efficient induction of human CD4+ T cell lines reactive with a self-K-ras-derived peptide in vitro, using a mAb to CD29.
    Hum Immunol. 1998 Jun;59(6):343-51.
34. Fujita H, et al.
    Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms.
    Eur J Immunol. 1998 Jan;28(1):305-16.
35. Zeki K, et al.
    Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53.
    Int J Cancer. 1998 Jan 30;75(3):391-5.
    PMID: 9455799; UI: 98115334.
36. Yokomizo H, et al.
    Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides.
    Hum Immunol. 1997 Jan;52(1):22-32.
    
    
    

3. T細胞による抗原認識と活性化シグナル

1. Tsukamoto, H.et al.
   B-Raf-mediated signaling pathway regulates T cell development.
   Eur. J. Immunol. 38: 518-527, 2008
2. Irie, A. et al.
   Protein kinase D2 contributes to either IL-2 promoter regulation or induction of cell death upon TCR-stimulation depending on its activity in Jurkat cells.
   Int. Immunol. 18: 1737-1747, 2006
3. Ohnishi, Y. et al.
   Altered peptide ligands control type II collagen-reactive T cells from rheumatoid arthritis patients.
   Mod. Rheumatol. 16: 226-228, 2006
4. Tsukamoto, H.et al.
   TCR ligand avidity determines the mode of B-Raf/Raf-1/ERK activation leading to the activation of human CD4⁺ T cell clone.
   Eur. J. Immunol. 36: 1926-1937, 2006
5. Kim, J-R.et al.
   A role of kinase inactive ZAP-70 in altered peptide ligand stimulated T cell activation
   Biochem. Biophys. Res. Comm. 341: 19-27, 2006
6. Chen, Y-Z.et al.
   Coculture of Th cells with IL-7 in the absence of antigenic stimuli induced T cell anergy reversed by IL-15.
   Human Immunol. 66: 677-687, 2005
7. Tsukamoto, H. et al.
   B-Raf contributes to sustained extracellular signal-regulated kinase activation associated with interleukin-2 production stimulated through the T cell receptor.
   J. Biol. Chem. 279: 48457-48465, 2004
8. Nishimura, Y.et al.
   Review, Degenerate recognition and response of human CD4⁺ Th cell clones: Implications for basic and applied immunology.
   Mol. Immunol. 40: 1089-1094, 2004
9. Irie, A . et al.
   Unique T-cell proliferation associated with PKCu activation and impaired Zap-70 phosphorylation in recognition of overexpressed HLA-DR/partially agonistic peptide complexes.
   Eur. J. Immunol. 33: 1497-1507, 2003
10. Uemura, Y. et al.
    [Review] Specificity, degeneracy, and molecular mimicry in antigen recognition by HLA-class II restricted T cell receptors; Implications for clinical medicine.
    Modern Rheumatology 13: 205-214, 2003
11. Uemura, Y. et al.
    Systematic analysis of the combinatorial nature of epitopes recognized by TCR leads to identification of mimicry epitopes for GAD65 specific TCRs
    J. Immunol. 170: 947-960, 2003
12. Kudo, H. et al.
    Cross-linking HLA-DR molecules on Th1 cells induces anaergy in association with increased level of cyclin-dependent kinase inhibitor p27Kip1.
    Immunol. Letters 81: 149-155, 2002
13. Fujii, S./Uemura, Y. et al.
    Establishment of an expression cloning system for CD4⁺ T cell epitopes.
    Biochem. Biophys. Res. Comm. 284: 1140-1147, 2001
14. Tabata H, et al.
    Ligation of HLA-DR molecules on B cells induces enhanced expression of IgM heavy chain genes in association with Syk activation.
    J Biol Chem. 275: 34998-35005, 2000
15. Lai ZF, Chen YZ, et al.
    An amiloride sensitive and voltage-dependent Na+ channel in a HLA-DR-restricted human T cell clone.
    J Immunol.2000 Jul;165(1):83-90
    PMID: 10861038; UI: 20318702
16. Tanaka Y, et al.
    Identification of Peptide Superagonists for a Self-K-ras-Reactive CD4+ T Cell Clone Using Combinatorial Peptide Libraries and Mass Spectrometry.
    J Immunol. 1999 Jun 15;162(12):7155-7161.
17. Chen YZ, et al.
    Modulation of calcium responses by altered peptide ligands in a human T cell clone.
    Eur J Immunol. 1998 Dec;28(12):3929-39.
18. Nishimura Y, et al.
    Modification of human T-cell responses by altered peptide ligands: a new approach to antigen-specific modification.
    Intern Med. 1998 Oct;37(10):804-17.
19. Fujii S, et al.
    The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
    Hum Immunol. 1998 Oct;59(10):607-14.
20. Matsushita S, et al.
    Evidence for self and nonself peptide partial agonists that prolong clonal survival of mature T cells in vitro.
    J Immunol. 1997 Jun 15;158(12):5685-91.
21. Chen YZ, et al.
    A single residue polymorphism at DR beta 37 affects recognition of peptides by T cells.
    Hum Immunol. 1997 Apr 15;54(1):30-9.
22. Matsushita S, et al.
    Partial activation of human T cells by peptide analogs on live APC: induction of clonal anergy associated with protein tyrosine dephosphorylation.
    Hum Immunol. 1997 Mar;53(1):73-80.
23. Matsuoka T, et al.
    Altered TCR ligands affect antigen-presenting cell responses: up-regulation of IL-12 by an analogue peptide.
    J Immunol. 1996 Dec 1;157(11):4837-43.
24. Chen YZ, et al.
    Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation.
    J Immunol. 1996 Nov 1;157(9):3783-90.
25. Ikagawa S, et al.
    Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism.
    J Allergy Clin Immunol. 1996 Jan;97(1 Pt 1):53-64.

4. 疾病とT細胞応答

1. Chen Y-Z, et al.
   Identification of SARS-CoV spike protein-derived and HLA-A2-restricted human CTL epitope by using a new muramyl dipeptide-derivative adjuvant.
   International Journal of Immunopathology and Pharmacology, 23:165-177, 2010.
   
2. Fukunaga T. et al.
   Relation between CD4(+) T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
   Am J Cardiol. 100: 483-488, 2007
3. Fukunaga T. et al.
   Expression of interferon-g and interleukin-4 production in CD4(+) T cells in patients with chronic heart failure.
   Heart and Vessels. 22: 178-83, 2007.
4. Soejima H. et al.
   Elevated plasma osteopontin levels were associated with osteopontin expression of CD4(+) T cells in patients with unstable angina.
   Circ. J. 70: 851-856, 2006.
5. Tanaka, T. et al.
   Comparison of frequency of interferon-gamma-positive CD4⁺ T cells before and after percutaneous coronary intervention and the effect of statin therapy in patients with stable angina pectoris.
   Am. J. Cardiol. 93: 1547-1549, 2004.
6. Soejima, H. at al.
   The preference to a Th1-type response in patients with coronary spastic angina.
   Circulation 107: 2196-2200, 2003.
7. Inoue, R. et al.
   Identification of b-lactoglobulin-derived peptides and class II HLA molecules recognized by T Cells from patients with milk allergy.
   Clin Exp Allergy. 31: 1126-1134, 2001.
8. Ohyama H, et al.
   T cell responses to 53-kDa outer membrane protein of Porphyromonas gingivalis in humans with early-onset periodontitis.
   Hum Immunol. 1998 Oct;59(10):635-43.